Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.80 |
| ▸ | KDR | P35968 | 15/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.74 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.74 |
| ▸ | FBP1 | P09467 | 3/20 | 0.74 |
| ▸ | CLK1 | P49759 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 1/20 | 0.74 |
| ▸ | INSR | P06213 | 1/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.74 |
| ▸ | FLT4 | P35916 | 1/20 | 0.74 |
| ▸ | TEK | Q02763 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.74 |
| ▸ | EPHA2 | P29317 | 9/20 | 0.72 |
| ▸ | FLT1 | P17948 | 3/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | JAK3 | P52333 | 1/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | KIF5B | P33176 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL907178 | 0.91 | KDR (0.69) | EGFRKDRERBB2EPHB4FBP1 | |
| SCHEMBL14095971 | 0.90 | EGFR (0.80) | EGFRKDRERBB2EPHB4FBP1 | |
| SCHEMBL22590721 | 0.89 | EGFR (0.80) | EGFRKDRERBB2EPHB4FBP1 | |
| SCHEMBL2100447 | 0.89 | KDR (0.80) | EGFRKDRERBB2EPHB4FBP1 | |
| SCHEMBL907424 | 0.87 | EGFR (0.61) | EGFRKDRERBB2EPHB4FBP1 | |
| SCHEMBL5570070 | 0.86 | EGFR (0.85) | EGFRKDRERBB2FBP1CLK1 | |
| SCHEMBL907172 | 0.86 | EPHA2 (0.81) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL6109882 | 0.86 | EPHA2 (0.81) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL907171 | 0.86 | EPHA2 (0.81) | EGFRKDRERBB2EPHB4EPHA2 | |
| SCHEMBL2099106 | 0.85 | EGFR (1.00) | EGFRKDRERBB2EPHB4FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SLC5A2, GCKR, IAPP | EGFR 3981/4885KDR 2859/4885ERBB2 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.